Stock TPST TEMPEST THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Tempest Therapeutics, Inc.

Equities

TPST

US87978U1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
3.54 USD +1.72% Intraday chart for Tempest Therapeutics, Inc. +14.19% -19.55%
Apr. 09 Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting CI
Apr. 04 Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications CI

Evolution of the average Target Price on Tempest Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

fed77f2efb43d0d64ede832c.l0LiAEAiUi-xETMSWvNu_Z7B3k6KZ4ooYSepP1Yqcrc.xw_TYndlAkPHaH14Np8fnva0qg3zKv1-Il_ETTNyJ_-6DLoyclM8a9Z4Zg~185e75528e82b4ec1b152d94fc40140e

Analyst Recommendations on Tempest Therapeutics, Inc.

Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13 MT
HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating MT
Piper Sandler Adjusts Tempest Therapeutics' Price Target to $6 From $10, Keeps Overweight Rating MT
Ladenburg Thalmann Starts Tempest Therapeutics at Buy With $8 Price Target MT
HC Wainwright Adjusts Tempest Therapeutics Price Target to $35 From $51, Maintains Buy Rating MT
Piper Sandler Adjusts Price Target on Tempest Therapeutics to $20 From $23, Reiterates Overweight Rating MT
TEMPEST THERAPEUTICS : William Blair Initiates Tempest Therapeutics at Outperform Rating MT
TEMPEST THERAPEUTICS : HC Wainwright Starts Tempest Therapeutics at Buy With $51 Price Target MT
TEMPEST THERAPEUTICS : Piper Sandler Starts Tempest Therapeutics at Overweight With $23 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.54 USD
Average target price
18.6 USD
Spread / Average Target
+425.42%
High Price Target
47 USD
Spread / Highest target
+1,227.68%
Low Price Target
8 USD
Spread / Lowest Target
+125.99%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Tempest Therapeutics, Inc.

Scotiabank
HC Wainwright
Piper Sandler
Ladenburg Thalmann
William Blair & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TPST Stock
  4. Consensus Tempest Therapeutics, Inc.